Compare Abbott Laboratories (ABT) vs Agilysys Inc (AGYS) Price & Performance

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Agilysys (AGYS) trades at $104.92, down 1.93% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2027 earnings beat expectations, driven by subscription growth and record revenue, prompting raised full-year guidance. The stock shows robust fundamentals with a 63.06% gross margin and 12.99% net income margin, though valuations are elevated with a P/E of 70.01. Institutional sentiment is positive, with all 9 analysts rating it a Buy and a consensus price target of $118.33.

Outlook remains favorable due to earnings momentum and AI-driven hospitality solutions, but risks include high valuation sensitivity and competitive pressures. Upside potential is supported by analyst targets, yet investors should monitor execution on growth forecasts and market volatility.